Key facts
- It has raised $13.4M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Plug and Play Tech Center, Yaletown Partners, Canaccord Genuity, Accelerate Fund, Alberta Cancer Foundation — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Syantra
- ·The full record, as it builds
Funding rounds
No funding rounds for Syantra are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syantra
Developer of precision healthcare screening tools and devices designed for early detection and diagnosis of cancer. The company's devices offer a blood-based cancer detection assay that utilizes a novel suite of biomarkers and proprietary artificial intelligence-generated algorithms to interpret data and provide a result of positive or negative, providing healthcare providers with a multifaceted tool for breast cancer diagnoses.
- Sector
- Healthcare
- HQ
- Calgary, Canada
- Founded
- 2013
- Employees
- 16
- Website
- syantra.com/
- Ownership
- Privately Held (backing)
Syantra doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syantra shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syantra in its N-PORT filings yet. We sweep new filings monthly.